Physician organization backs universal single payer system

The out-of-pocket cost for MS disease-modifying therapies jump by 217% going from $750 per year in 2012 to $2,378 per year in 2021.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Roche’s Evrysdi is the market leader among the drugs for spinal muscular atrophy. Biogen’s Spinraza has struggled, but company officials express confidence about future sales.

On financial toxicity, and when, how and by whom it should be discussed.